PLASMA & ERYTHROCYTE FATTY ACIDS IN TREATED CHILDREN W/ PKU

等离子体

• 批准号: 6565710
• 负责人: LOUIS J ELSAS
• 金额: $ 29.31万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-12-01 至 2002-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6565710
• 关键词: child (0-11); clinical research; diet therapy; dietary supplements; erythrocytes; essential fatty acids; fatty acids; human subject; human therapy evaluation; metabolism disorder chemotherapy; nutrient requirement; nutrition related tag; oral administration; phenylketonurias; plasma; siblings

This proposal is designed to test the hypotheses that: 1) there are no differences in the intake of essential fatty acids (EFAS) among groups of children with PKU fed different medical foods and normal children, and 2) there are no differences in the plasma and erythrocyte fatty acids among groups of children undergoing therapy for PKU with different medical foods and normal children. The investigators will compare EFA intake of children undergoing therapy for PKU who are ingesting Lofenalac, Phenex, Phenyl-free or XP Maximaid to intakes of their normal siblings. Plasma and erythrocyte fatty acid profiles of children undergoing therapy for PKU who are ingesting Lofenalac, Phenex, Phenyl-free, or XP Maxamaid will be compared to the fatty acid profiles of their normal siblings.

本研究旨在验证以下假设：1）不同医疗食品喂养的PKU儿童组与正常儿童组之间的必需脂肪酸（EFAS）摄入量无差异; 2）接受不同医疗食品治疗的PKU儿童组与正常儿童组之间的血浆和红细胞脂肪酸无差异。研究人员将比较正在接受苯丙酮尿症治疗的儿童的EFA摄入量，这些儿童服用了Lofenalac，Phenex，Phenyl free或XP Maximaid，并与他们正常的兄弟姐妹进行了比较。将接受Lofenalac、Phenex、Phenyl free或XP Maxamaid治疗的PKU儿童的血浆和红细胞脂肪酸谱与其正常同胞的脂肪酸谱进行比较。